Literature DB >> 15066666

Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism.

Nadia Maria Volpato1, Regina Lengruber Silva, Ana Paula P Brito, José Carlos S Gonçalves, Mário Vaisman, François Noël.   

Abstract

In a previous study aimed to compare the bioavailability of two levothyroxine tablets, we found a good relation between their pharmacokinetics parameters and dissolution profiles, employing the USP dissolution conditions in use at that time (24th edition). Despite the formulations were considered bioequivalent, the test product presented values of AUC and concentrations at steady-state significantly lower (about 10%) than the reference ones. The purpose of the present study was to evaluate if the actual pharmacopeial conditions (with alterations introduced in the first supplement of USP 24) would also allow a good correlation between bioavailability and dissolution data. The partial AUCs were correlated with cumulative levothyroxine amount dissolved at three different times, for each dissolution condition. Employing the old method, test tablets had a slower dissolution rate than the reference ones, resulting in a quite good multiple level C in vitro/in vivo (IVIV) correlation. On the other hand, the very fast dissolution profiles obtained in the actual condition lead to a worse IVIV correlation. Present work indicates that the mild conditions proposed in the older US Pharmacopeia were better than the actual in order to discriminate dissolution profiles of levothyroxine tablets which present subtle, but significant, differences in their pattern of absorption.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15066666     DOI: 10.1016/j.ejps.2004.01.006

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  An investigation into the influence of experimental conditions on in vitro drug release from immediate-release tablets of levothyroxine sodium and its relation to oral bioavailability.

Authors:  Ivana Kocic; Irena Homsek; Mirjana Dacevic; Jelena Parojcic; Branislava Miljkovic
Journal:  AAPS PharmSciTech       Date:  2011-07-12       Impact factor: 3.246

2.  Development and application of a validated HPLC method for the analysis of dissolution samples of levothyroxine sodium drug products.

Authors:  J W Collier; R B Shah; A R Bryant; M J Habib; M A Khan; P J Faustino
Journal:  J Pharm Biomed Anal       Date:  2010-10-13       Impact factor: 3.935

3.  Sustained Administration of Hormones Exploiting Nanoconfined Diffusion through Nanochannel Membranes.

Authors:  Thomas Geninatti; R Lyle Hood; Giacomo Bruno; Priya Jain; Eugenia Nicolov; Arturas Ziemys; Alessandro Grattoni
Journal:  Materials (Basel)       Date:  2015-08-13       Impact factor: 3.623

4.  Fabrication of novel elastosomes for boosting the transdermal delivery of diacerein: statistical optimization, ex-vivo permeation, in-vivo skin deposition and pharmacokinetic assessment compared to oral formulation.

Authors:  Diana E Aziz; Aly A Abdelbary; Abdelhalim I Elassasy
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

5.  Formulation of Lipid-Based Tableted Spray-Congealed Microparticles for Sustained Release of Vildagliptin: In Vitro and In Vivo Studies.

Authors:  Khaled H Al Zahabi; Hind Ben Tkhayat; Ehab Abu-Basha; Al Sayed Sallam; Husam M Younes
Journal:  Pharmaceutics       Date:  2021-12-15       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.